You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究上調麗珠醫藥(01513.HK)目標價至45.2元 評級「買入」
阿思達克 09-29 10:03
匯豐研究發表報告,指出將麗珠醫藥(01513.HK)2021及2022年的收入預測分別上調3%及5%,2020及2022年的純利預測則分別上調10%、10%及11%,主要是基於COVID-19診斷套件銷售強勁,及上半年銷售開支減少。

該行預期,受到主要產品的高知名度及輔助藥物銷售疲弱影響消退,料公司2020至2022年的收入年複合增長率為13%。而盈利的年複合增長率為15%,較收入的增速為快,因為毛利率表現改善、銷售開支比率下降等因素所致。

該行認為公司的估值吸引,而研發進度的因素並不在股價上反映出來,預計將會有重新評級的機會,料其渠道將會在2021至2022年有成果。該行維持「買入」投資評級,目標價由原來的37元上調至45.2元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account